18F-Clofarabine PET Imaging for Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the drug 18F-Clofarabine for cancer treatment?
Clofarabine, a component of 18F-Clofarabine, has shown effectiveness in treating blood cancers like acute myeloid leukemia and acute lymphoblastic leukemia, and it has been approved for use in certain pediatric leukemia cases. Additionally, combining clofarabine with imaging techniques has shown promise in liver cancer studies, suggesting potential for broader cancer applications.12345
Is 18F-Clofarabine safe for humans?
Clofarabine has been used in various studies for treating leukemia, showing some common side effects like low blood cell counts, nausea, and liver enzyme changes. Serious side effects were less common, but included conditions like capillary leak syndrome and liver issues. Overall, it has been considered to have an acceptable safety profile in heavily pretreated patients.35678
How is the drug 18F-Clofarabine unique for cancer treatment?
18F-Clofarabine is unique because it is used as a PET imaging probe to measure the expression of a specific enzyme (deoxycytidine kinase) in tumors, which can help predict how well a tumor will respond to certain cancer drugs. This imaging approach is different from traditional treatments as it focuses on assessing the tumor's characteristics rather than directly treating the cancer.123910
Research Team
Roberto Vargas, MD
Principal Investigator
Cleveland Clinic, Case Comprehensive Cancer Center
Eligibility Criteria
This trial is for adults over 18 with metastatic carcinoma or adenocarcinoma, confirmed by imaging. Participants must have measurable disease, be able to stay still for an hour during imaging, and have normal organ function levels. It's not suitable for those with recent severe heart issues, significant bleeding, stroke risks, or pregnant/breastfeeding women.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Observation
Participants receive a CFA injection and undergo a PET/CT scan to measure DCK activity. They are observed for side effects.
Follow-up
Participants are contacted the next day to inquire about any side effects. If routine care involves repeat imaging, the CFA PET/CT scan may be repeated up to 365 days later.
Treatment Details
Interventions
- 18F-Clofarabine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roberto Vargas
Lead Sponsor
Omar Mian
Lead Sponsor